NCT04662944 - A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections | Biotech Hunter

Enrollment

494

Participants

Timeline

Start Date

February 23, 2021

Primary Completion Date

June 28, 2023

Study Completion Date

June 28, 2023

Conditions

Neovascular Age-Related Macular Degeneration

Interventions

DRUG

brolucizumab

There was no treatment allocation. Patients administered Brolucizumab by prescription that started before inclusion of the patient into the study were enrolled.

DRUG

ranibizumab

There was no treatment allocation. Patients administered Ranibizumab by prescription that started before inclusion of the patient into the study were enrolled.

DRUG

aflibercept

There was no treatment allocation. Patients administered Aflibercept by prescription that started before inclusion of the patient into the study were enrolled.

Trial Locations (17)

20132

Novartis Investigative Site, Milan

20157

Novartis Investigative Site, Milan

24080

Novartis Investigative Site, León

37075

Novartis Investigative Site, Göttingen

40212

Novartis Investigative Site, Düsseldorf

41930

Novartis Investigative Site, Bormujos

48145

Novartis Investigative Site, Münster

48327

Novartis Investigative Site, Waterford

53105

Novartis Investigative Site, Bonn

71638

Novartis Investigative Site, Ludwigsburg

89075

Novartis Investigative Site, Ulm

L8G 5E4

Novartis Investigative Site, Hamilton

M8X 2X3

Novartis Investigative Site, Toronto

H1V 1G5

Novartis Investigative Site, Montreal

D09 YN97

Novartis Investigative Site, Glasnevin

08035

Novartis Investigative Site, Barcelona

08036

Novartis Investigative Site, Barcelona